The global expansion of Chinese biotech companies accelerated in the first quarter, with the number of overseas deals surging 18 per cent year on year, showing strong momentum in the field of drugs research, according to a new report.
Chinese drug makers landed 33 deals with overseas healthcare firms in the first three months of this year, with transactions totalling US$36.2 billion, according to a report published on Wednesday by mainland pharmaceutical and biotech consultancy DrugTimes.
